SEARCH

SEARCH BY CITATION

References

  • Anton, A.H. & Sayre, D.F. (1962). A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J. Pharmacol. Exp. Ther., 138, 360375.
  • Behrman, H.R. (1979). Prostaglandins in hypothalamopituitary and ovarian function. Annu. Rev. Physiol., 41, 685700.
  • Brooks, D.P., Share, L. & Crofton, J.T. (1986). Role of brain prostaglandins in the control of vasopressin secretion in the conscious rat. Endocrinology, 118, 17161722.
  • Bunce, K.T., Clayton, N.M., Coleman, R.A., Collington, E.W., Finch, H., Humphray, J.M., Humphrey, P.P.A., Reeves, J.J., Sheldrick, R.L.G. & Stables, R. (1990). GR63799X-a novel prostanoid with selectivity for EP3-receptors. Adv. Prostaglandin Thromboxane Leukot. Res., 21, 379382.
  • Chiu, E.K.Y. & Richardson, J.S. (1983). Cardiovascular responses to central and peripheral prostaglandins in the anesthetized rat. Eur. J. Pharmacol., 87, 714.
  • Coceani, F., Lees, J. & Bishai, I. (1988). Further evidence implicating prostaglandin E2 in the genesis of pyrogen fever. Am. J. Physiol., 254, R463R469.
  • Coleman, R.A., Kennedy, I. & Sheldrick, R.L.G. (1985). AH6809, a prostanoid EP1 receptor blocking drug. Br. J. Pharmacol., 85, 273P.
  • Coleman, R.A., Kennedy, I. & Sheldrick, R.L.G. (1987a). Evidence for the existence of three subtypes of PGE2 sensitive (EP) receptors in smooth muscle. Br. J. Pharmacol., 91, 323P.
  • Coleman, R.A., Kennedy, I., Sheldrick, R.L.G. & Tolowinska, I.Y. (1987b). Further evidence for the existence of three subtypes of PGE2-sensitive (EP-) receptors. Br. J. Pharmacol., 91, 407P.
  • Coleman, R.A., Smith, W.L. & Narumiya, S. (1994). Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46, 205229.
  • Dong, Y.J., Jones, R.L. & Wilson, N.H. (1986). Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br. J. Pharmacol., 87, 97107.
  • Ferreira, S.H., Lorenzetti, B.B. & Correa, F.M.A. (1978). Central and peripheral antialgesic action of aspirin-like drugs. Eur. J. Pharmacol., 53, 3948.
  • Feuerstein, G., Adelberg, S.A., Kopin, I.J. & Jacobowitz, D.M. (1982). Hypothalamic sites for cardiovascular and sympathetic modulation by prostaglandin E2. Brain Res., 231, 335342.
  • Gardiner, P.J. (1986). Characterization of prostanoid relaxant/inhibitory receptors (ψ) using a highly selective agonist, TR 4979. Br. J. Pharmacol., 87, 4556.
  • Heaulme, M. & Dray, F. (1984). Noradrenaline and prostaglandin E2 stimulate LH-RH release from rat median eminence through distinct 1-alpha-adrenergic and PGE2 receptors. Neuroendocrinology, 39, 403407.
  • Hoffman, W.E. & Schmid, P.G. (1979). Cardiovascular and antidiuretic effects of central prostaglandin E2. J. Physiol., 28, 159169.
  • Johnson, R.W., Curtis, S.E., Dantzer, R. & Kelley, K.W. (1993). Central and peripheral prostaglandins are involved in sickness behavior in birds. Physiol. Behav., 53, 127131.
  • Kandasamy, S.B. & Williams, B.A. (1982). Prostacyclin-induced hyperthermia: Implication of a protein mediator. Neuropharmacology, 21, 10651072.
  • Kennedy, I., Coleman, R.A., Humphrey, P.P.A., Levy, G.P. & Lumley, P. (1982). Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins, 24, 667689.
  • Lawrence, R.A., Jones, R.L. & Wilson, N.H. (1989). Relaxant properties of prostaglandin E analogues on rabbit jugular vein. Br. J. Pharmacol., 98, 796P.
  • Lawrence, R.A., Jones, R.L. & Wilson, N.H. (1992). Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br. J. Pharmacol., 105, 271278.
  • Mantelli, L., Amerini, S., Rubino, A. & Ledda, F. (1991). Prejunctional prostanoid receptors on cardiac adrenergic terminals belong to the EP3 subtype. Br. J. Pharmacol., 102, 573576.
  • Milton, A.S. (1989). Thermoregulatory actions of eicosanoids in the central nervous system with particular regard to the pathogenesis of fever. Ann. N.Y. Acad. Sci., 559, 392410.
  • Okuma, Y., Yokotani, K. & Osumi, Y. (1991). Chemical sympathectomy with 6-hydroxydopamine potentiates intracerebroventricularly applied bombesin-induced increase in plasma adrenaline. Life Sci., 49, 16111618.
  • Okuno, T., Lindheimer, M.D. & Oparil, S. (1982). Central effects of prostaglandin E2 on blood pressure and plasma renin activity in rats; role of the sympathoadrenal system and vasopressin. Hypertension, 4, 809816.
  • Paxinos, G. & Watson, C. (ed). (1986). The Rat Brain in Stereotaxic Coordinates. Boston: Academic Press, Inc.
  • Sanner, J.H. (1969). Antagonism of prostaglandin E2 by 1-acetyl-2(8-chloro-10, 11-dihydrobenz (b, f) (1, 4) oxazepine-10-carbonyl) hydrazine (SC-19220). Arch. Int. Pharmacodyn. Ther., 180, 4656.
  • Smith, W.L. (1992). Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol., 263, F181F191.
  • Sonnenburg, W.K. & Smith, W.L. (1988). Regulation of cyclic AMP metabolism in rabbit cortical collecting tubule cells by prostaglandins. J. Biol. Chem., 263, 61556160.
  • Sugimoto, Y., Shigemoto, R., Namba, T., Negishi, M., Misuno, N., Narumiya, S. & Ichikawa, A. (1994). Distribution of the messenger RNA for the prostaglandin E receptor subtype EP3 in the mouse nervous system. Neuroscience, 62, 919928.
  • Swanson, L.W. & Sawchenko, P.E. (1983). Hypothalamic integration: Organization of the paraventricular and supraoptic nuclei. Annu. Rev. Neurosci., 6, 269324.
  • Wolfe, L.S. (1982). Eicosanoids: Prostaglandins, thromboxanes, leukotrienes, and other derivatives of carbon-20 unsaturated fatty acids. J. Neurochem., 38, 114.
  • Yokotani, K. & Osumi, Y. (1993). Cholinergic M2 muscarinic receptor-mediated inhibition of endogenous noradrenaline release from the isolated vascularly perfused rat stomach. J. Pharmacol. Exp. Ther., 264, 5460.
  • Yokotani, K., Yokotani, K., Okuma, Y. & Osumi, Y. (1988). Sympathoadrenomedullary system mediation of the prostaglandin E2-induced central inhibition of gastric acid output in rats. J. Pharmacol. Exp. Ther., 244, 335340.